Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | PI4KA | P42356 | 8/20 | 0.43 |
| ▸ | PI4K2B | Q8TCG2 | 8/20 | 0.43 |
| ▸ | PI4K2A | Q9BTU6 | 8/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 8/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18776139 | 0.76 | ADORA2A (0.56) | ADORA2AADORA1NUDT1TSHRPI4KA | |
| SCHEMBL4424909 | 0.76 | ADORA2A (0.56) | ADORA2AADORA1NUDT1TSHRPI4KA | |
| SCHEMBL7267919 | 0.72 | ADORA2A (0.47) | ADORA2AADORA1NUDT1TSHRPI4KA | |
| SCHEMBL459827 | 0.71 | METAP2 (0.39) | — | |
| SCHEMBL17440085 | 0.70 | ADORA2A (0.49) | ADORA2AADORA1NUDT1TSHRPI4KA | |
| SCHEMBL29454410 | 0.70 | ADORA2A (0.61) | ADORA2AADORA1NUDT1TSHRPI4KA | |
| SCHEMBL42335 | 0.70 | ADORA2A (0.61) | ADORA2AADORA1NUDT1TSHRPI4KA | |
| SCHEMBL42314 | 0.69 | ADORA2A (0.66) | ADORA2AADORA1NUDT1TSHRPI4KA | |
| SCHEMBL29400753 | 0.69 | ADORA2A (0.66) | ADORA2AADORA1NUDT1TSHRPI4KA | |
| SCHEMBL669407 | 0.69 | PI4KA (0.56) | ADORA2AADORA1NUDT1TSHRPI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401829-B1 | NOVEL HETEROCYCLIC ANTIBACTERIAL COMPOUNDS | MICROBIOTIX INC (US) | 2012-08-22 | — | — | EP | disclosed |
| US-7585851-B2 | 3′-prodrugs of 2′-deoxy-β-L-nucleosides | IDENIX PHARMACEUTICALS, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| EP-1401829-A4 | NOVEL HETEROCYCLIC ANTIBACTERIAL COMPOUNDS | MICROBIOTIX INC (US) | 2004-10-27 | — | — | EP | disclosed |
| US-6777420-B2 | A URACIL COMPOUNDS AS ENZYME INHIBITORS, INHIBIT BACTERIAL DNA POLYMERASE, TREATING BACTERIAL DISEASES | MICROBIOTIX, INC. | 2004-08-17 | — | — | US | disclosed |
| EP-1401829-A1 | NOVEL HETEROCYCLIC ANTIBACTERIAL COMPOUNDS | Microbiotix, Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030181719-A1 | Novel heterocyclic antibacterial compounds | MICROBIOTIX, INC. | 2003-09-25 | — | — | US | disclosed |
| WO-2002102792-A1 | NOVEL HETEROCYCLIC ANTIBACTERIAL COMPOUNDS | MICROBIOTIX, INC. (US) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181719-A1 | Novel heterocyclic antibacterial compounds | TOP1, TOP2A, TOP2B | ADORA2A 4346/4885ADORA1 4699/4885NUDT1 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.